Literature DB >> 24836991

Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions.

Sezai Çelik1, Chiara Lestuzzi2, Eugenio Cervesato3, Didier Dequanter4, Patrizia Piotti5, Marzia De Biasio6, Massimo Imazio7.   

Abstract

OBJECTIVE: Our aim was to compare systemic chemotherapy (CT) with drainage and with pericardial window in the treatment of neoplastic pericarditis in patients with various malignancies included in the International Neoplastic Pericarditis Treatment study.
METHODS: Patients treated with systemic CT alone (Group A), CT plus drainage (Group B), or CT plus pericardial window (Group C) were included. Treatment response was defined as complete response (ie, no more pericardial effusion or masses), partial response (ie, reduced total score, without requiring further treatments), stable disease (ie, unchanged total score), or progressive disease (ie, increased total score). Patients with partial or complete response were considered responders.
RESULTS: This preliminary report included 175 patients (56.6% male) with a mean age of 54.21±14.26 years. Gender distribution, age, and follow-up duration was similar for all groups (P>.05). Prevalent cancer types were lung cancer (50.9%), breast cancer (14.9%), and lymphoma/leukemia (14.9%). Overall, 22.3%, 42.9%, and 34.9% of patients were in treatment group A, B, and C, respectively. There were 132 responders (75.3%). The rate of responders significantly differed between groups (P<.001); it was significantly higher in Group B than in Group A (P<.05) and in Group C than in Group B (P=.006). The significant factors affecting response were therapy (P=.002) and extent of effusion (P=.037). Kaplan-Meier analysis showed that patients in Group C had a significantly better survival rate than patients in the other groups (P=.001).
CONCLUSIONS: Systemic CT plus pericardial window is a more effective treatment option compared with systemic CT alone and systemic CT plus drainage in patients with malignant effusions.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24836991     DOI: 10.1016/j.jtcvs.2014.04.031

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  11 in total

1.  Symptomatic malignant pericardial effusion due to advanced pericardial malignancies: a palliative approach.

Authors:  Nauman Khalid; Lovely Chhabra; Sarah Aftab Ahmad; David H Spodick
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

2.  Pulmonary hypertension concurrent with pericardial effusion and superior vena cava syndrome: who is the initiator?

Authors:  Bei-Ning Wang; Yu-Xi Li; Wei Ma; Song-Yun Chu; Zhi-Hao Liu; Wen-Hui Ding; Jian-Ping Li
Journal:  J Geriatr Cardiol       Date:  2020-11-28       Impact factor: 3.327

3.  Pericardiocentesis versus pericardiotomy for malignant pericardial effusion: a retrospective comparison.

Authors:  C Labbé; L Tremblay; Y Lacasse
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

Review 4.  Pericardial Disease Associated with Malignancy.

Authors:  Ryan Schusler; Shari L Meyerson
Journal:  Curr Cardiol Rep       Date:  2018-08-20       Impact factor: 2.931

5.  A Life-Threatening Presentation of Primary Small Cell Colorectal Non-Hodgkin Lymphoma as Cardiac Tamponade and Its Challenging Management.

Authors:  Amr Elkammash; Mohamed Ayman Abdel-Hay; Saleh Kanaan; Mustafa Alsinan; Yosra Taha; Mohammed Fadul; Nourhan Degheidy
Journal:  Eur J Case Rep Intern Med       Date:  2021-08-06

6.  Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.

Authors:  Danielle El Haddad; Cezar Iliescu; Syed Wamique Yusuf; William Nassib William; Tarif H Khair; Juhee Song; Elie N Mouhayar
Journal:  J Am Coll Cardiol       Date:  2015-09-08       Impact factor: 24.094

7.  Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion.

Authors:  Gianmauro Numico; Antonella Cristofano; Marcella Occelli; Marco Sicuro; Alessandro Mozzicafreddo; Elena Fea; Ida Colantonio; Marco Merlano; Pierluigi Piovano; Nicola Silvestris
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

8.  Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy.

Authors:  Bob T Li; Antonia Pearson; Nick Pavlakis; David Bell; Adrian Lee; David Chan; Michael Harden; Manu Mathur; David Marshman; Peter Brady; Stephen Clarke
Journal:  J Clin Med       Date:  2014-12-30       Impact factor: 4.241

Review 9.  Pericardial Disease in Cancer Patients.

Authors:  Arjun K Ghosh; Tom Crake; Charlotte Manisty; Mark Westwood
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-06-23

10.  Effectiveness and outcomes of 2 therapeutic interventions for cardiac tamponade: A retrospective observational study.

Authors:  Hady Zgheib; Cynthia Wakil; Sami Shayya; Rana Bachir; Mazen El Sayed
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.